Diabetic foot ulcers (DFUs) are a serious and common complication of diabetes mellitus, often associated with peripheral neuropathy, poor vascular supply, infection, and delayed wound healing, frequently leading to amputation. Emerging evidence highlights mitochondrial dysfunction as a key factor in the development of diabetic complications, making it an important therapeutic target. Mitochondria play a vital role in cellular energy production, and their impairment contributes to metabolic imbalance, increased oxidative stress, and disrupted lipid metabolism. In diabetes, this dysfunction reduces the ability of cells to adapt to stress and maintain viability, accelerating complications such as neuropathy and impaired wound healing.

This case report describes an 80-year-old male with a long-standing history of diabetes, peripheral vascular disease, severe neuropathy, Charcot joint deformity, and osteomyelitis. He presented with a chronic, non-healing diabetic foot ulcer and was advised of amputation. Instead, he underwent a comprehensive treatment approach including wound debridement, infection control, antibiotics, metabolic stabilization, and BIONICA-MDI therapy. Over four months, he received 45 sessions of BIONICA-MDI along with supportive growth factors and peptides.

The patient demonstrated significant clinical improvement, including reduced infection, progressive wound healing, and eventual complete closure of the ulcer with stable scarring. Signs of enhanced vascularization and tissue regeneration, including osteogenesis and chondrogenesis, were observed. Systemic symptoms such as recurrent fever also resolved.

BIONICA-MDI therapy works by mimicking the body’s natural pulsatile insulin delivery, stimulating hepatic metabolic pathways essential for ATP production. This helps restore glucose and lipid metabolism, reduce metabolic stress, and improve cellular energy balance. The therapy also enhances insulin sensitivity and supports key metabolic processes.

Overall, this case highlights the potential of BIONICA-MDI therapy as an effective adjunct in managing complex DFUs by targeting mitochondrial function, reducing inflammation, and promoting tissue repair, warranting further clinical investigation.

Dr. Pradeep V Mahajan completed his master's in general surgery from Marathwada University, Maharashtra, and went on to pursue a Diploma in Urology at the University of Vienna, Austria. In a career-changing move, after three decades of being a successful general and Uro-surgeon, he started his brainchild - StemRx Bioscience Solutions Pvt. Ltd. in the year 2011. This was to focus on in-depth research in the field of Regenerative Medicine and Cell-Based Therapy, which he believes is the solution to address the limitations of conventional therapeutic modalities. To this end, he has undergone and continues to undergo intensive training in the United States. He has devised personalized treatment protocols for more than 100 health conditions using cell-based therapy. Dr. Mahajan has published 38 research articles in International and National Journals. He has a patent for Avascular Necrosis and is on the board for reviewing scholarly articles for various international journals. Dr. Mahajan has received many international awards for his pioneering research work in regenerative medicine.